Increasing spread of Candida auris and investigation of risk factors for invasive infections in colonized patients
The Journal of Infection in Developing Countries · 2025
DOI: 10.3855/jidc.20891 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Tuğba Arslan Gülen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Türkiye. Hauptthemen laut MEDLINE: Candida auris, Candidiasis, Candidiasis, Invasive, Candida. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Candida auris is a yeast that has a high mortality rate in critically ill patients and is resistant to many antifungal agents enhancing its clinical importance. Our study identifies the risk factors for C. auris invasive infection, antifungal susceptibility, and outcomes. Methodology: A total of 100 adults with C. auris isolated in any clinical specimen between 07.01.2022 and 31.12.2023 were enrolled in this retrospective cohort study. Data were obtained via retrospective screening of patient files. C. auris identification was performed by MALDI-TOF MS. Antifungal susceptibility was carried out by VITEK 2 and CDC methodology. Colonized and infected patients were compared to assess the risk factors for and outcomes of invasive infection.
Results
Twenty (20%) patients developed invasive infections, with 16 (80%) having candidemia. Age, Candida score, prior antifungal agent use, number of previously used antibiotics ≥ 3, presence of central venous catheter or nasogastric catheter, and being monitored out of burn unit were the risk factors, and Candida score was identified as an independent risk factor for invasive infection development. Of the isolates, 55% were resistant to fluconazole and 100% were resistant to amphotericin B. No micafungin resistance was detected. The overall mortality rate in patients with invasive infection was 75%.
Conclusions
Knowing the risk factors for invasive infection will help early initiation of empirical antifungal therapy by ensuring early identification of high-risk patients, and Candida score appears to be an effective method for this. Revealing antifungal susceptibility will also guide the selection of appropriate empirical treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Türkiye.
- Department of Medical Mycology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Türkiye.
- Department of General Surgery, University of Health Sciences, Adana City Training and Research Hospital, Adana, Türkiye.
- Department of Anesthesiology and Intensive Care, University of Health Sciences, Adana City Training and Research Hospital, Adana, Türkiye.
- Hospital Infection Control Committee, Adana City Training and Research Hospital, Adana, Türkiye.
Zitieren
APA
Arslan Gülen, T., Akar, N., Oruç, E., Turunç, T., Daş, K., Ünlü, N., & Uğurbekler, A. (2025). Increasing spread of Candida auris and investigation of risk factors for invasive infections in colonized patients. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.20891
Vancouver
Arslan Gülen T, Akar N, Oruç E, Turunç T, Daş K, Ünlü N, et al. Increasing spread of Candida auris and investigation of risk factors for invasive infections in colonized patients. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.20891
BibTeX
@article{ArslanGlen2025,
author = {Arslan Gülen, Tuğba and Akar, Nida and Oruç, Ebru and Turunç, Tuba and Daş, Koray and Ünlü, Nurdan and Uğurbekler, Aygün},
title = {Increasing spread of Candida auris and investigation of risk factors for invasive infections in colonized patients},
journal = {The Journal of Infection in Developing Countries},
year = {2025},
doi = {10.3855/jidc.20891}
}
EUVIMED